Search research articles
Contact Us
Filters
Showing results (411-420 of 578) with videos related to
Page
of 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2016
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Alexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Gynecologic Oncology
|
September 2, 2018
The genetic landscape of 87 ovarian germ cell tumors
Els Van Nieuwenhuysen, Pieter Busschaert, Patrick Neven, et al.
The Oncologist
|
December 14, 2024
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25
Coline Montégut, Claire Falandry, Saverio Cinieri, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 10, 2021
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis
Joanna Baum, Elena Ioana Braicu, Oliver Hunsicker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Cancer Reports (Hoboken, N.J.)
|
February 22, 2023
Systematic study of tissue factor expression in solid tumors
Johann S de Bono, Jeffrey R Harris, Saskia M Burm, et al.
Archives of Pathology & Laboratory Medicine
|
December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?
Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
Page
of 58
Search research articles
Search
Showing results (411-420 of 578) with videos related to
Sort By:
Page
of 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2016
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Alexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Gynecologic Oncology
|
September 2, 2018
The genetic landscape of 87 ovarian germ cell tumors
Els Van Nieuwenhuysen, Pieter Busschaert, Patrick Neven, et al.
The Oncologist
|
December 14, 2024
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25
Coline Montégut, Claire Falandry, Saverio Cinieri, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 10, 2021
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis
Joanna Baum, Elena Ioana Braicu, Oliver Hunsicker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Cancer Reports (Hoboken, N.J.)
|
February 22, 2023
Systematic study of tissue factor expression in solid tumors
Johann S de Bono, Jeffrey R Harris, Saskia M Burm, et al.
Archives of Pathology & Laboratory Medicine
|
December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?
Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
Page
of 58